BR112022007410A2 - Compostos de 4-aminoisoindolina-1,3-diona substituída e segundos agentes ativos para uso combinado - Google Patents
Compostos de 4-aminoisoindolina-1,3-diona substituída e segundos agentes ativos para uso combinadoInfo
- Publication number
- BR112022007410A2 BR112022007410A2 BR112022007410A BR112022007410A BR112022007410A2 BR 112022007410 A2 BR112022007410 A2 BR 112022007410A2 BR 112022007410 A BR112022007410 A BR 112022007410A BR 112022007410 A BR112022007410 A BR 112022007410A BR 112022007410 A2 BR112022007410 A2 BR 112022007410A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- aminoisoindoline
- substituted
- combined use
- active agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSTOS DE 4-AMINOISOINDOLINA-1,3-DIONA SUBSTITUÍDA E SEGUNDOS AGENTES ATIVOS PARA USO COMBINADO. A presente invenção refere-se a métodos para usar (S)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona, ou um enantiômero, mistura de enantiômeros, tautômero, isotopólogo, ou sal farmaceuticamente aceitável do mesmo, em combinação com a segundo agente ativo para tratar, prevenir ou gerenciar malignidades hematológicas. O segundo agente ativo é um ou mais dentre um inibidor HDAC, um inibidor BCL2, um inibidor BTK, um inibidor mTOR, um inibidor PI3K, um inibidor PKCß, um inibidor SYK, um inibidor JAK2, um inibidor de Aurora quinase, um inibidor EZH2, um inibidor BET, a agente hipometilante, um inibidor DOT1L, um inibidor HAT, um inibidor WDR5, um inibidor DNMT1, um inibidor LSD-1, um inibidor G9A, um inibidor PRMT5, um inibidor BRD, um inibidor SUV420H1/H2, um inibidor CARM1, um inibidor PLK1, um inibidor NEK2, um inibidor MEK, um inibidor PHF19, um inibidor PIM, um inibidor IGF-1R, um inibidor XPO1, um inibidor BIRC5, ou a quimioterapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962923945P | 2019-10-21 | 2019-10-21 | |
PCT/US2020/056439 WO2021080955A1 (en) | 2019-10-21 | 2020-10-20 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022007410A2 true BR112022007410A2 (pt) | 2022-07-05 |
Family
ID=73449178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022007410A BR112022007410A2 (pt) | 2019-10-21 | 2020-10-20 | Compostos de 4-aminoisoindolina-1,3-diona substituída e segundos agentes ativos para uso combinado |
Country Status (12)
Country | Link |
---|---|
US (2) | US11583536B2 (pt) |
EP (1) | EP4048260A1 (pt) |
JP (1) | JP2022552880A (pt) |
KR (1) | KR20220103951A (pt) |
CN (2) | CN115607552A (pt) |
AU (1) | AU2020372334A1 (pt) |
BR (1) | BR112022007410A2 (pt) |
CA (1) | CA3154923A1 (pt) |
CL (1) | CL2022000995A1 (pt) |
IL (1) | IL292263A (pt) |
MX (1) | MX2022004729A (pt) |
WO (1) | WO2021080955A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200143454A (ko) * | 2018-04-13 | 2020-12-23 | 스미토모 다이니폰 파마 온콜로지, 인크. | 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제 |
MX2021009371A (es) | 2019-02-12 | 2021-09-10 | Sumitomo Pharma Oncology Inc | Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos. |
WO2023091932A1 (en) * | 2021-11-17 | 2023-05-25 | Cardiff Oncology, Inc. | Cancer treatment using lsd1 inhibitors and plk1 inhibitors |
CN117402178B (zh) * | 2023-12-15 | 2024-03-08 | 英矽智能科技(上海)有限公司 | 作为jak抑制剂和phd抑制剂的嘧啶类化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018346395A1 (en) * | 2017-10-05 | 2020-04-30 | Mecox Curemed Co., Ltd. | Oral bendamustine formulations |
JP7458324B2 (ja) | 2018-04-23 | 2024-03-29 | セルジーン コーポレイション | 置換された4-アミノイソインドリン-1,3-ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
-
2020
- 2020-10-20 EP EP20807561.4A patent/EP4048260A1/en active Pending
- 2020-10-20 KR KR1020227016736A patent/KR20220103951A/ko unknown
- 2020-10-20 CN CN202211310591.3A patent/CN115607552A/zh active Pending
- 2020-10-20 CA CA3154923A patent/CA3154923A1/en active Pending
- 2020-10-20 BR BR112022007410A patent/BR112022007410A2/pt unknown
- 2020-10-20 AU AU2020372334A patent/AU2020372334A1/en active Pending
- 2020-10-20 MX MX2022004729A patent/MX2022004729A/es unknown
- 2020-10-20 WO PCT/US2020/056439 patent/WO2021080955A1/en active Application Filing
- 2020-10-20 JP JP2022523517A patent/JP2022552880A/ja active Pending
- 2020-10-20 US US17/075,496 patent/US11583536B2/en active Active
- 2020-10-20 CN CN202080086473.1A patent/CN114786665A/zh active Pending
-
2022
- 2022-04-13 IL IL292263A patent/IL292263A/en unknown
- 2022-04-20 CL CL2022000995A patent/CL2022000995A1/es unknown
-
2023
- 2023-01-23 US US18/100,426 patent/US20230158037A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2022000995A1 (es) | 2022-11-04 |
IL292263A (en) | 2022-06-01 |
CN114786665A (zh) | 2022-07-22 |
US20210113576A1 (en) | 2021-04-22 |
CA3154923A1 (en) | 2021-04-29 |
WO2021080955A1 (en) | 2021-04-29 |
EP4048260A1 (en) | 2022-08-31 |
AU2020372334A1 (en) | 2022-05-05 |
US11583536B2 (en) | 2023-02-21 |
MX2022004729A (es) | 2022-05-13 |
KR20220103951A (ko) | 2022-07-25 |
US20230158037A1 (en) | 2023-05-25 |
CN115607552A (zh) | 2023-01-17 |
JP2022552880A (ja) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022007410A2 (pt) | Compostos de 4-aminoisoindolina-1,3-diona substituída e segundos agentes ativos para uso combinado | |
AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
EA202191903A1 (ru) | Антипролиферативные соединения и вторые активные агенты для комбинированного применения | |
MA27703A1 (fr) | Derives de diazepino-indole servant d'inhibiteurs de kinases | |
MX2019013954A (es) | Inhibidores covalentes de kras. | |
CO2017011038A2 (es) | Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca” | |
Cunha et al. | Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A 1 and A 2A receptor activation | |
JP2018528192A5 (pt) | ||
AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
AR056346A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
JP2009541223A5 (pt) | ||
PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
RU2015143438A (ru) | Фармацевтическая композиция, содержащая активатор амрк и серотонинергическое средство, и способы ее применения | |
RU2013129820A (ru) | Замещенные бензопиразиновые производные в качестве ингибиторов fgfr-киназ для лечения раковых заболеваний | |
CO5190708A1 (es) | Mezcla sinergica para el tratamiento del sindrome de piernas inquietas | |
NZ752918A (en) | Treatment of prostate cancer | |
CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
RU2008115239A (ru) | 7-[2-[4-(6-фтор-3-метил-1, 2-бензизоксазол-5-ил)-1-пиперазинил]этил]-2-(пропинил)-7h-пиразоло-[4,3-е]-[1,2,4]-триазоло-[1,5-с]пиримидин-5-амин | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
BR112022026090A2 (pt) | Métodos para tratar câncer com terapias de combinação | |
BR112019003197A2 (pt) | compostos contendo espirocíclicos e seus usos farmacêuticos | |
DOP2023000271A (es) | Derivados de la urea que pueden ser utilizados para tratar el cáncer | |
BR112022010319A2 (pt) | Uso de bi853520 no tratamento de câncer | |
BR112021024380A2 (pt) | Formulações de liberação modificadas e usos das mesmas |